Leah Cann
Stock Analyst at Brookline Capital
(1.32)
# 2,522
Out of 4,420 analysts
11
Total ratings
42.86%
Success rate
8.51%
Average return
Main Sectors:
Top Industries:
8 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MEIP MEI Pharma | Maintains: Buy | $80 | $3.20 | +2,400.00% | 2 | May 23, 2023 | |
| CRBU Caribou Biosciences | Initiates: Buy | $19 | $3.83 | +396.08% | 1 | Feb 14, 2022 | |
| AGIO Agios Pharmaceuticals | Assumes: Perform | n/a | $33.22 | - | 2 | Feb 20, 2019 | |
| EXEL Exelixis | Upgrades: Outperform | n/a | $21.90 | - | 2 | Feb 27, 2018 | |
| NTLA Intellia Therapeutics | Initiates: Perform | n/a | $23.72 | - | 1 | Jul 18, 2017 | |
| EDIT Editas Medicine | Initiates: Perform | n/a | $5.66 | - | 1 | Jul 18, 2017 | |
| CRSP CRISPR Therapeutics AG | Initiates: Perform | n/a | $57.06 | - | 1 | Jul 18, 2017 | |
| VSTM Verastem | Initiates: Outperform | n/a | $11.84 | - | 1 | Apr 13, 2017 |
MEI Pharma
May 23, 2023
Maintains: Buy
Price Target: $80
Current: $3.20
Upside: +2,400.00%
Caribou Biosciences
Feb 14, 2022
Initiates: Buy
Price Target: $19
Current: $3.83
Upside: +396.08%
Agios Pharmaceuticals
Feb 20, 2019
Assumes: Perform
Price Target: n/a
Current: $33.22
Upside: -
Exelixis
Feb 27, 2018
Upgrades: Outperform
Price Target: n/a
Current: $21.90
Upside: -
Intellia Therapeutics
Jul 18, 2017
Initiates: Perform
Price Target: n/a
Current: $23.72
Upside: -
Editas Medicine
Jul 18, 2017
Initiates: Perform
Price Target: n/a
Current: $5.66
Upside: -
CRISPR Therapeutics AG
Jul 18, 2017
Initiates: Perform
Price Target: n/a
Current: $57.06
Upside: -
Verastem
Apr 13, 2017
Initiates: Outperform
Price Target: n/a
Current: $11.84
Upside: -